
Cristiana Fodor

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8366411/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Robotic Image-Guided Stereotactic Radiotherapy, for Isolated Recurrent Primary, Lymph Node or Metastatic Prostate Cancer. International Journal of Radiation Oncology Biology Physics, 2012, 82, 889-897.	0.4	221
2	Anthracycline-induced cardiotoxicity: A multicenter randomised trial comparing two strategies for guiding prevention with enalapril: The International CardioOncology Society-oneÂtrial. European Journal of Cancer, 2018, 94, 126-137.	1.3	163
3	Preliminary Results of Electron Intraoperative Therapy Boost and Hypofractionated External Beam Radiotherapy After Breast-Conserving Surgery in Premenopausal Women. International Journal of Radiation Oncology Biology Physics, 2008, 72, 485-493.	0.4	74
4	Linac-based Stereotactic Body Radiotherapy for Oligometastatic Patients With Single Abdominal Lymph Node Recurrent Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2014, 37, 227-233.	0.6	71
5	Salvage Stereotactic Body Radiotherapy for Isolated Lymph Node Recurrent Prostate Cancer: Single Institution Series of 94 Consecutive Patients and 124 Lymph Nodes. Clinical Genitourinary Cancer, 2017, 15, e623-e632.	0.9	71
6	Stereotactic Body Radiation Therapy for Oligometastatic Ovarian Cancer: A Step Toward a Drug Holiday. International Journal of Radiation Oncology Biology Physics, 2018, 101, 650-660.	0.4	65
7	Use of machine learning methods for prediction of acute toxicity in organs at risk following prostate radiotherapy. Medical Physics, 2011, 38, 2859-2867.	1.6	60
8	Reirradiation for isolated local recurrence of prostate cancer: Mono-institutional series of 64 patients treated with salvage stereotactic body radiotherapy (SBRT). British Journal of Radiology, 2019, 92, 20180494.	1.0	50
9	Correlation Between Acute and Late Toxicity in 973 Prostate Cancer Patients Treated With Three-Dimensional Conformal External Beam Radiotherapy. International Journal of Radiation Oncology Biology Physics, 2010, 78, 26-34.	0.4	48
10	Sooner or Later? Outcome Analysis of 431 Prostate Cancer Patients Treated With Postoperative or Salvage Radiotherapy. International Journal of Radiation Oncology Biology Physics, 2009, 74, 115-125.	0.4	42
11	Salvage image-guided intensity modulated or stereotactic body reirradiation of local recurrence of prostate cancer. British Journal of Radiology, 2015, 88, 20150197.	1.0	38
12	Dose Escalation for Prostate Cancer Using the Three-Dimensional Conformal Dynamic Arc Technique: Analysis of 542 Consecutive Patients. International Journal of Radiation Oncology Biology Physics, 2008, 71, 784-794.	0.4	31
13	Acute toxicity of image-guided hypofractionated radiotherapy for prostate cancer: Nonrandomized comparison with conventional fractionation. Urologic Oncology: Seminars and Original Investigations, 2011, 29, 523-532.	0.8	28
14	CyberKnife robotic image-guided stereotactic radiotherapy for oligometastic cancer. Strahlentherapie Und Onkologie, 2013, 189, 448-455.	1.0	26
15	Radiation-induced acute dysphagia. Strahlentherapie Und Onkologie, 2017, 193, 971-981.	1.0	22
16	Long-Term Results and Reconstruction Failure in Patients Receiving Postmastectomy Radiation Therapy with a Temporary Expander or Permanent Implant in Place. Plastic and Reconstructive Surgery, 2020, 145, 317-327.	0.7	22
17	[11C]Choline PET/CT Impacts Treatment Decision Making in Patients With Prostate Cancer Referred for Radiotherapy. Clinical Genitourinary Cancer, 2014, 12, 155-159.	0.9	20
18	Role of EGFR as prognostic factor in head and neck cancer patients treated with surgery and postoperative radiotherapy: proposal of a new approach behind the EGFR overexpression. Medical Oncology, 2017, 34, 107.	1.2	20

Cristiana Fodor

#	Article	lF	CITATIONS
19	Image Guided Hypofractionated Radiotherapy and Quality of Life for Localized Prostate Cancer: Prospective Longitudinal Study in 337 Patients. Journal of Urology, 2013, 189, 2099-2103.	0.2	19
20	Stereotactic body radiotherapy for castration-sensitive prostate cancer bone oligometastases. Medical Oncology, 2018, 35, 75.	1.2	19
21	Late toxicity of image-guided hypofractionated radiotherapy for prostate: non-randomized comparison with conventional fractionation. Radiologia Medica, 2019, 124, 65-78.	4.7	17
22	ecancermedicalscience. Ecancermedicalscience, 2014, 8, 405.	0.6	16
23	Hypofractionated postmastectomy radiotherapy with helical tomotherapy in patients with immediate breast reconstruction: dosimetric results and acute/intermediate toxicity evaluation. Medical Oncology, 2018, 35, 39.	1.2	16
24	Multi atlas based segmentation: should we prefer the best atlas group over the group of best atlases?. Physics in Medicine and Biology, 2018, 63, 12NT01.	1.6	16
25	Rationale and Protocol of AIRC IG-13218, Short-Term Radiotherapy for Early Prostate Cancer with Concomitant Boost to the Dominant Lesion. Tumori, 2016, 102, 536-540.	0.6	15
26	Evaluation of late rectal toxicity after conformal radiotherapy for prostate cancer. Strahlentherapie Und Onkologie, 2009, 185, 384-389.	1.0	14
27	Intensity-modulated radiotherapy (IMRT) in the treatment of squamous cell anal canal cancer: acute and early-late toxicity, outcome, and efficacy. International Journal of Colorectal Disease, 2020, 35, 685-694.	1.0	14
28	Prostate positioning using cone-beam computer tomography based on manual soft-tissue registration. Strahlentherapie Und Onkologie, 2014, 190, 81-87.	1.0	13
29	Stereotactic radiation therapy in oligometastatic colorectal cancer: outcome of 102 patients and 150 lesions. Clinical and Experimental Metastasis, 2019, 36, 331-342.	1.7	13
30	Phase II Multi-institutional Clinical Trial on a New Mixed Beam RT Scheme of IMRT on Pelvis Combined with a Carbon Ion Boost for High-risk Prostate Cancer Patients. Tumori, 2017, 103, 314-318.	0.6	12
31	Mould-based surface high-dose-rate brachytherapy for eyelid carcinoma. Journal of Contemporary Brachytherapy, 2019, 11, 443-448.	0.4	10
32	Concurrent cisplatin, continuous infusion fluorouracil and radiotherapy followed by tailored consolidation treatment in non metastatic anal squamous cell carcinoma. BMC Cancer, 2011, 11, 55.	1.1	9
33	Electronic portal imaging registration in breast cancer radiotherapy verification: Analysis of inter-observer agreement among different categories of health practitioners. Neoplasma, 2013, 60, 302-308.	0.7	9
34	Urinary Bladder Preservation for Muscle-invasive Bladder Cancer: A Survey among Radiation Oncologists of Lombardy, Italy. Tumori, 2015, 101, 174-178.	0.6	9
35	Image-Guided Radiotherapy for Prostate Cancer using 3 Different Techniques: Localization Data of 186 Patients. Tumori, 2015, 101, 273-280.	0.6	9
36	VERO® radiotherapy for low burden cancer: 789 patients with 957 lesions. Ecancermedicalscience, 2016, 10, 677.	0.6	9

#	Article	IF	CITATIONS
37	Short-term high precision radiotherapy for early prostate cancer with concomitant boost to the dominant lesion: ad interim analysis and preliminary results of Phase II trial AIRC-IG-13218. British Journal of Radiology, 2018, 91, 20160725.	1.0	9
38	Radioablation +/â^' hormonotherapy for prostate cancer oligorecurrences (Radiosa trial): potential of imaging and biology (AIRC IG-22159). BMC Cancer, 2019, 19, 903.	1.1	9
39	Ductal carcinoma in situ and intraoperative partial breast irradiation: Who are the best candidates? Long-term outcome of a single institution series. Radiotherapy and Oncology, 2019, 133, 68-76.	0.3	9
40	"Give me five―ultra-hypofractionated radiotherapy for localized prostate cancer: non-invasive ablative approach. Medical Oncology, 2018, 35, 96.	1.2	8
41	HALFMOON TomoTherapy (Helical ALtered Fractionation for iMplant partial OmissiON): implant-sparing post-mastectomy radiotherapy reshaping the clinical target volume in the reconstructed breast. Journal of Cancer Research and Clinical Oncology, 2019, 145, 1887-1896.	1.2	8
42	Intra- and inter-observer variability in breast tumour bed contouring and the controversial role of surgical clips. Medical Oncology, 2019, 36, 51.	1.2	8
43	Local Failure After Accelerated Partial Breast Irradiation with Intraoperative Radiotherapy with Electrons: An Insight into Management and Outcome from an Italian Multicentric Study. Annals of Surgical Oncology, 2020, 27, 752-762.	0.7	8
44	Reporting combined outcomes with Trifecta and survival, continence, and potency (SCP) classification in 337 patients with prostate cancer treated with image-guided hypofractionated radiotherapy. BJU International, 2014, 114, E3-E10.	1.3	7
45	No increase in toxicity of pelvic irradiation when intensity modulation is employed: clinical and dosimetric data of 208 patients treated with post-prostatectomy radiotherapy. British Journal of Radiology, 2016, 89, 20150985.	1.0	7
46	Stereotactic body radiation therapy for mediastinal lymph node metastases: how do we fly in a â€~no-fly zone'?. Acta Oncológica, 2018, 57, 1532-1539.	0.8	7
47	Phase II prospective trial "Give Me Five―short-term high precision radiotherapy for early prostate cancer with simultaneous boost to the dominant intraprostatic lesion: the impact of toxicity on quality of life (AIRC IG-13218). Medical Oncology, 2020, 37, 74.	1.2	7
48	Radiotherapy in Prostate Cancer Patients With Pelvic Lymphocele After Surgery: Clinical and Dosimetric Data of 30 Patients. Clinical Genitourinary Cancer, 2015, 13, e223-e228.	0.9	6
49	Cone-beam CT-based inter-fraction localization errors for tumors in the pelvic region. Physica Medica, 2018, 46, 59-66.	0.4	6
50	A global Unified Dosimetry Index (gUDI) to evaluate simultaneous integrated boost radiotherapy plans in prostate cancer. Radiotherapy and Oncology, 2018, 128, 315-320.	0.3	6
51	Comparison of Outcomes and Toxicity Between Extreme and Moderate Radiation Therapy Hypofractionation in Localized Prostate Cancer: A Propensity Score Analysis. International Journal of Radiation Oncology Biology Physics, 2019, 105, 735-744.	0.4	6
52	Case series on multiple prostate re-irradiation for locally recurrent prostate cancer: something ventured, something gained. Neoplasma, 2019, 66, 308-314.	0.7	6
53	Impact of image guidance on toxicity and tumour outcome in moderately hypofractionated external-beam radiotherapy for prostate cancer. Medical Oncology, 2019, 36, 9.	1.2	6
54	High-dose-rate Brachytherapy as Adjuvant Local rEirradiation for Salvage Treatment of Recurrent breAst cancer (BALESTRA): aAretrospective mono-institutional study. Journal of Contemporary Brachytherapy, 2020, 12, 207-215.	0.4	6

Cristiana Fodor

#	Article	IF	CITATIONS
55	A Model to Predict Upstaging to Invasive Carcinoma in Patients Preoperatively Diagnosed with Low-Grade Ductal Carcinoma In Situ of the Breast. Cancers, 2022, 14, 370.	1.7	6
56	High-Dose-Rate Interstitial Brachytherapy in Early Stage Buccal Mucosa and Lip Cancer: Report on the Consecutive 12 Patients and Review of the Literature. Tumori, 2012, 98, 471-477.	0.6	5
57	High-Risk Prostate Cancer and Radiotherapy: The Past and the Future. A Benchmark for a New Mixed Beam Radiotherapy Approach. Clinical Genitourinary Cancer, 2017, 15, 376-383.	0.9	5
58	Cytoreductive prostate radiotherapy in oligometastatic prostate cancer: a single centre analysis of toxicity and clinical outcome. Ecancermedicalscience, 2017, 11, 786.	0.6	5
59	Genital marginal failures after intensity-modulated radiation therapy (IMRT) in squamous cell anal cancer: no higher risk with IMRT when compared to 3DCRT. Medical Oncology, 2018, 35, 59.	1.2	5
60	Bladder preservation in non-metastatic muscle-invasive bladder cancer (MIBC): a single-institution experience. Ecancermedicalscience, 2016, 10, 657.	0.6	4
61	High precision radiotherapy including intensity-modulated radiation therapy and pulsed-dose-rate brachytherapy for cervical cancer: a retrospective monoinstitutional study. Journal of Contemporary Brachytherapy, 2019, 11, 516-526.	0.4	4
62	Ultrahypofractionated radiotherapy for localized prostate cancer with simultaneous boost to the dominant intraprostatic lesion: a plan comparison. Tumori, 2022, 108, 263-269.	0.6	4
63	Predictors of positive axillary non-sentinel lymph nodes in breast cancer patients with positive sentinel lymph node biopsy after neoadjuvant systemic therapy. Radiotherapy and Oncology, 2021, 163, 128-135.	0.3	4
64	Finding safe dose-volume constraints for re-irradiation with SBRT of patients with prostate cancer relapse: The IEO experience. Physica Medica, 2021, 92, 62-68.	0.4	4
65	Nonrandomized Comparison between Concomitant and Sequential Chemoradiotherapy with Anthracyclines in Breast Cancer. Tumori, 2015, 101, 64-71.	0.6	3
66	Implant risk failure in patients undergoing postmastectomy 3-week hypofractionated radiotherapy after immediate reconstruction. Radiotherapy and Oncology, 2021, 163, 105-113.	0.3	3
67	Second Malignancies following Breast Cancer Treatment: A Case-Control Study Based on the Peridose Methodology. ALLEGRO Project (Task 5.4). Tumori, 2012, 98, 715-721.	0.6	2
68	Adjuvant radiotherapy treatment for soft tissue sarcoma of extremities and trunk. A retrospective mono-institutional analysis. Neoplasma, 2021, 67, 1447-1455.	0.7	2
69	Acute and intermediate toxicity of 3-week radiotherapy with simultaneous integrated boost using TomoDirect: prospective series of 287 early breast cancer patients. Clinical and Translational Oncology, 2021, 23, 1415-1428.	1.2	2
70	Ultra-hypofractionated whole breast adjuvant radiotherapy in the real-world setting: single experience with 271 elderly/frail patients treated with 3D and IMRT technique. Journal of Cancer Research and Clinical Oncology, 2022, 148, 823-835.	1.2	2
71	EP-1338: High precision radiotherapy for early prostate cancer with concomitant boost to the dominant lesion. Radiotherapy and Oncology, 2017, 123, S717-S718.	0.3	1
72	Dosimetric study to assess the feasibility of intraoperative radiotherapy with electrons (ELIOT) as partial breast irradiation for patients with cardiac implantable electronic device (CIED). Breast Cancer Research and Treatment, 2018, 171, 693-699.	1.1	1

CRISTIANA FODOR

#	Article	IF	CITATIONS
73	Comparing TomoHelical and TomoDirect in postmastectomy hypofractionated radiotherapy after immediate breast reconstruction. Physica Medica, 2021, 90, 66-72.	0.4	1
74	Lung optimized treatment with CyberKnife® in inoperable lung cancer patients: feasibility analysis of a mono-institutional 115 patient series. Neoplasma, 2020, 67, 684-691.	0.7	1
75	Mixed-Beam Approach for High-Risk Prostate Cancer Carbon-Ion Boost Followed by Photon Intensity-Modulated Radiotherapy: Preliminary Results of Phase II Trial AIRC-IG-14300. Frontiers in Oncology, 2021, 11, 778729.	1.3	1
76	The POLO (Partially Omitted Lobe) approach to safely treat in-breast recurrence after intraoperative radiotherapy with electrons. British Journal of Radiology, 2022, 95, 20210405.	1.0	1
77	Radiotherapy Plus Total Androgen Block Versus Radiotherapy Plus LHRH Analog Monotherapy for Non-metastatic Prostate Cancer. Anticancer Research, 2018, 38, 3139-3143.	0.5	Ο
78	Second malignancies following breast cancer treatment: a case-control study based on the Peridose methodology. Allegro project (task 5.4). Tumori, 2012, 98, 715-21.	0.6	0